A novel oral vaccine, ETVAX, has demonstrated its potential to reduce paediatric cases of moderate-to-severe enterotoxigenic ...
Maze is catching up with Vertex which is also developing a drug with the same target for APOL1-mediated kidney disease.
Lilly received approval of Kisunla in the US in 2024. Credit: Michael Vi / Shutterstock.com On 20 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related ...
C4 Therapeutics plans cemsidomide combination studies targeting more data and strategy updates by mid-2026. Credit: AnnaStills / Shutterstock.com. C4 Therapeutics has begun dosing in a Phase Ib study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results